Research in Cancer Supportive Care and Survivorship


Dr. Alexandre Chan

Associate Professor, Department of Pharmacy, National University of Singapore
Associate Professor, Duke-NUS Graduate Medical School
Specialist Pharmacist (Oncology Pharmacy), National Cancer Center Singapore

A/Prof. Alexandre Chan, Pharm.D., MPH, FCCP, BCPS, BCOP is a Deputy Head (Clinical) and a tenured Associate Professor at Department of Pharmacy, Faculty of Science at National University of Singa­pore (NUS). He is also appointed as an adjunct faculty at University of California, San Francisco School of Pharmacy and University of the Pacif­ic Thomas J. Long School of Pharmacy and Health Sciences. In addition, he is the programme director for the National Oncol­ogy Pharmacy Residency Program in Singapore.


Prof. Chan earned his Doctor of Pharmacy degree from Rutgers University, and his Master of Public Health from National University of Singapore. He has completed a Pharmacy Prac­tice Residency (PGY-1) at University of California San Francisco, School of Pharmacy and an Oncology Specialty Residency (PGY-2) at University of Cal­ifornia Davis Medical Center. Currently, he is dually board certified in Pharma­cotherapy and Oncology Pharmacy. As a clinician scientist, Prof. Chan is heavily involved in cancer research. He has great interest in cancer supportive care with an emphasis on understanding the biological mechanisms, clinical prediction and management strategies of chemotherapy-induced and cancer-related toxicities in cancer patients and survivors. He has a strong interest in cancer pharmacoepidemiology, medication safety in oncology and clinical pharmacy education.


Prof. Chan supervises Pharm.D. and PhD students, residents and fellows, and his research program has attracted over US$ 1.7 million dollars of funding support from numerous agencies and pharmaceutical companies at national and international level, and he was the recipient of the Young Scientist Award from National University of Singapore in 2013, and he was also elected as an American College of Clinical Pharmacy (ACCP) Fellow in 2014. He has published over 120 full-length peer-reviewed manuscripts in a wide array of cancer supportive care topics, including chemotherapy-induced nausea and vomiting, myelosuppression, cognitive impairment, dermatological toxicities and cancer-related fatigue. Prof. Chan is also serving as a leader in various international organizations, including American College of Clinical Pharmacy, International Society of Oncology Pharmacy Practitioners and Multinational Association of Supportive Care in Cancer.

Through delivering state-of-the art patient care and conducting meaningful clinical, translational and outcomes research, we aim to improve the supportive and pharmaceutical care in patients with cancer. Our diverse clinical and research interests include the development of novel monitoring and management strategies of toxicities with cytotoxic chemotherapies and novel targeted therapies, identification and development of preventive strategies of clinically significant drug-drug interactions associated with anticancer treatments, and cost-effective usage of medicine in patients with cancer.

We are actively seeking for Postgraduate Students and Post-Doctorate Fellows who are interested in our research!
If you would to join our team, please email Associate Professor Alex Chan at

  1. Teleni L, Chan RJ, Chan A, Isenring EA, Vela I, Inder W, McCarthy AL. Exercise improves quality of life in ADT-treated prostate cancer: systematic review of RCTs. Endocr Relat Cancer 2015; doi: 10.1530/ERC-15-0456.
  2. Suzuki S, Chan A, Nomura H, Johnson PE, Endo K, Saito S. Chemotherapy regimen checks performed by pharmacists contribute to safe administration of chemotherapy. J Oncol Pharm Pract 2015; doi: 10.1177/1078155215614998.
  3. Marx W, McKavanagh D, McCarthy AL, Bird R, Ried K, Chan A, Isenring L. The effect of ginger (Zingiber officinale) on platelet aggregation: a systematic literature review. PLOS ONE 2015; Accepted for Publication.
  4. Loh KY, Ng T, Lee CP, Ng R, Chan A. Medication Use by Early-Stage Breast Cancer Survivors: A 1-Year Longitudinal Study. Support Care Cancer 2015; Accepted for Publication.
  5. Ng T, Teo SM, Yeo HL, Shwe M, Gan YX, Cheung YT, Foo KM, Cham MT, Lee JA, Tan YP, Fan G, Yong WS, Preetha M, Loh WK, Koo SL, Jain A, Lee GE, Wong M, Dent R, Yap YS, Ng R, Khor CC, Ho HK, Chan A. Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. Neuro Oncol 2015; doi:10.1093/neuonc/nov162.
  6. Lao CK, Chan YM, Tong HHY, Chan A. Under-diagnosis of depression in an economically deprived population in Macao, China. Asia Pac Psychiatry 2015; doi: 10.1111/appy.12208
  7. Chan A, Song M, Langit MR, Lim TA, Fong W, Tay K, Lim ST, Tang T. Carotid artery inflammation associated with gemcitabine-based therapy: a special report. Future Oncology 2015;11(14):2049-58.
  8. Chan RJ, Chan A. Survivorship care provision for patients with hematologic malignancies: The quest for quality evidence. Cancer Nursing 2015;38(5):414-5.
  9. Cheung YT, Ong YY, Ng T, Tan YP, Fan G, Chan CW, Molassiotis A, Chan A. Assessment of mental health literacy in patients with breast cancer. J Onc Pharm Pract 2015; DOI: 10.1177/1078155215587541.
  10. Langbecker D, Ekberg S, Yates P, Chan A, Chan RJ. What are the barriers of quality survivorship care for haematology cancer patients? Qualitative insights from cancer nurses. J Cancer Surviv 2015; DOI: 10.1007/s11764-015-0458-7
  11. Lao CK, Chan YM, Tong HHY, Chan A. Prevalence, Awareness and Control of Cardiovascular Risk Factors in a Low-Income Population in Macao, China. Public Health Research 2015; 5(2):50-57.
  12. Cheung YT, Ng T, Shwe M, Ho HK, Foo KM, Cham MT, Lee JA, Fan G, Tan YP, Yong WS, Madhukumar P, Loo SK, Ang SF, Wong M, Chay WY, Ooi WS, Dent RA, Yap YS, Ng R, Chan A. Association of pro-inflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: A multi-centered, prospective, cohort study. Ann Oncol 2015;26(7):1446-51.
  13. Ng T, Toh MR, Cheung YT, Chan A. Follow-up care practices and barriers to breast cancer survivorship: Perspectives from Asian Oncology Practitioners. Support Care Cancer 2015. Epub DOI: 10.1007/s00520-015-2700-2
  14. Teo YL, Wee HL, Chue XP, Chau NM, Tan MH, Kanesvaran R, Wee HL, Ho HK, Chan A. Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestion of toxicities from sunitinib in Asian patients. Pharmacogenomics Journal 2015. Epub DOI: 10.1038/tpj.2015.13
  15. Goldspiel B, Sewell G, Chan A. Happy 20th Birthday to JOPP. J Onc Pharm Pract 2015; 21(2): 83-84.
  16. Chan A, Cameron MC, Garden B, Boers-Doets CB, Schindler K, Epstein JB, Choi J, Beamer L, Roeland E, Russi EG, Bensadoun RJ, Teo YL, Chan RJ, Shih V, Bryce J, Raber-Durlacher J, Gerber PA, Freytes CO, Rapoport B, LeBoeuf N, Sibaud V, Lacouture ME. A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therpaies. Support Care Cancer 2015; DOI: 10.1007/s00520-014-2564-x.
  17. Chan RJ, McCarthy AL, Devenish J, Sullivan KA, Chan A. Systematic review of pharmacologic and non-pharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer. European Journal of Cancer 2015; 51(4):437-450
  18. Wang XJ, Lopez SE, Chan A. Economic Burden of Chemotherapy-Induced Febrile Neutropenia in Patients with Lymphoma: A Systematic Review. Crit Rev Heme Onc 2015;94(2):201-12
  19. Teo YL, Wee HL, Chue XP, Chau NM, Tan MH, Kanesvaran R, Wee HL, Ho HK, Chan A. Association of drug exposure with toxicity and clinical response in metastatic renal-cell carcinoma patients receiving an attenuated dosing regimen of sunitinib. Target Oncol 2014; DOI: 10.1007/s11523-014-0349-2
  20. Chan A, Lim E, Ng T, Shih V, Quek R, Cheung YT. Symptom burden and Medication use in Adult Sarcoma Patients. Support Care Cancer 2014;23(6):1709-17.
  21. Tan HS, Li H, Hong YW, Toh CK, Wong A, Lopes G, Tay MH, Chan A, Yao X, Tang T, Ng QS, Kanesvaran R, Chau NM, Tan MH. Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results from a Prospective Registry in Singapore. Clin Gen Cancer 2014; DOI:10.1016/j.clgc.2014.11.004.
  22. Teo YL, Ho HK, Chan A. Formation of reactive metabolites and management of tyrosine kinase inhibitor induced hepatotoxicity: a literature review. Expert Opin Drug Metab Toxicol 2014; 15: 1-12.
  23. Ng T, Khor CC, Ho HK, Chan A. The Genetic Variants Underlying Breast Cancer Treatment-Induced Chronic and Late Toxicities: A Systematic Review. Cancer Treatment Reviews 2014; 40(10):1199-1214.
  24. Wang XJ, Wong M, Hsu LY, Chan A. Cost associated with febrile neutropenia in solid tumor and lymphoma patients – an observational study in Singapore. BMC Health Services Research 2014; 14: 434
  25. Teo YL, Ho HK, Chan A. Metabolism-related pharmacokinetic drug-drug interactions in tyrosine kinase inhibitors: current understanding, challenges and recommendations. Br J Clin Pharmacol 2015;79(2):241-5
  26. Keefe DM, Chan A, Kim HK, Hsieh RK, Yu S, Wang Y, Nicholls RJ, Burke TA. Rationale and design of the Pan Australasian chemotherapy-induced emesis burden of illness study. Support Care Cancer 2014;23(1):253-61.
  27. Kim HK, Hsieh RK, Chan A, Yu S, Han B, Gao Y, Baños A, Ying X, Burke T, Keefe D. Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice. Support Care Cancer 2014;23(1):293-300.
  28. Hsieh RK, Chan A, Kim HK, Yu S, Kim JG, Lee MA, Dalén J, Jung H, Liu YP, Burke T, Keefe D. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer 2014;23(1):263-72
  29. Yu S, Burke T, Chan A, Kim HK, Hsieh RK, Hu X, Liang JT, Baños A, Spiteri C, Keefe D. Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy—a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. Support Care Cancer 2014; 23(1):273-82.
  30. Chan A, Kim HK, Hsieh RK, Yu S, Lopez G, Su WC, Baños A, Bhatia S, Burke T, Keefe D. Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice – a longitudinal analysis. Support Care Cancer 2014; 23(1):283-91.
  31. Pachman DR, Watson JC, Lustberg MB, Wagner-Johnston ND, Chan A, Broadfield L, Cheung YT, Steer C, Storey DJ, Chandwani KD, Paice J, Jean-Pierre P, Oh J, Kamath J, Fallon M, Strik H, Koeppen S, Loprinzi CL. Management options for established chemotherapy-induced peripheral neuropathy. Support Care Cancer 2014; 22(8):2281-95.
  32. Chan A, Shwe M, Gan YX, Yap K, Chew L, Lim WT. Trajectory and Risk Factors for Chemotherapy-induced Nausea and Vomiting in Asian Head and Neck Cancer Patients. Head Neck 2014; DOI 10.1002/hed.23753
  33. Teo YL, Chue XP, Chau NM, Tan MH, Wee HL, Ho HK, Kanesvaran R, Chan A. Toxicities and patient reported outcomes in elderly Asian patients receiving an attenuated dosing of sunitinib for metastatic renal cell carcinoma. J Geriatr Oncol 2014; 5 S1:S19
  34. Yap K, Chia Y, Low XH, Chan A. Technological preferences of aging cancer patients for delivery services and devices to solve drug-related problems in oncology. Support Care Cancer 2014; 22(10):2733-40.
  35. Chan A, Lees J, Keefe D. The Changing Paradigm for Supportive Care in Cancer Patients. Support Care Cancer 2014;22(6):1441-5.
  36. Ko Y, Gwee YS, Huang YC, Chiang J, Chan A. Costs and Length of Stay of Drug-Related Hospital Admissions in Cancer Patients. Clin Ther 2014; 36(4): 588-92.
  37. See M, Shih V, Ho HK, Tang T, Farid M, Quek R, Tao M, Lim ST, Chan A. A Pilot Study to Evaluate the Role of Therapeutic Drug Monitoring of Pegfilgrastim in Lymphoma Patients Receiving Chemotherapy. Proceedings of Singapore Healthcare 2014; 23(1): 13-20.
  38. Chan A, Soh D, Ko Y, Huang YC, Chiang J. Characteristics of Unplanned Hospital Admissions due to Drug Related Problems in Cancer Patients. Support Care Care 2014; 22(7): 1875-81.
  39. Cheung YT, Foo YL, Shwe M, Tan YP, Fan G, Yong WS, Preetha M, Ooi WS, Chay WY, Dent R, Ang SF, Lo SK, Yap YS, Ng R, Chan A. Evaluated Minimal Clinically Important Difference in Perceived Cognitive Disturbances among Patients with Breast Cancer. J Clin Epidemiology 2014; 67(7):811-20.
  40. Chan A, Wong QX, Karah Ali M, Wong M, Hsu LY. Clinical Efficacy of Adjunctive G-CSF on Solid Tumor and Lymphoma Patients with Established Febrile Neutropenia. Support Care Cancer 2014; 22(4):1105–1112.
  41. Teo YL, Chong XJ, Chue XP, Chau NM, Tan MH, Kanesvaran R, Wee HL, Ho HK, Chan A. Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo and outcomes investigation. Cancer Clin Pharmacology 2014; 73(2): 381-8.
  42. Cheung YT, Lim SR, Ho HK, Chan A. Cytokines as Mediators of Chemotherapy-associated Cognitive Changes: Current Evidence, Limitations and Directions for Future Research. PLOS ONE 8(12): e81234. doi:10.1371/journal.pone.0081234
  43. Engle JP, Erstad BL, Anderson DC, Bucklin MH, Chan A, Donaldson AR, Hagemann TM, O’Connor MB, Rodgers PT, Tennant S, Thomas Z. Minimum Qualifications for Clinical Pharmacy Practice Faculty. Pharmacotherapy 2014;34(5):e38–e44.
  44. Poon KSH, Un MK, Low XH, Cheung YT, Yap KYL, Chan A. Impact of cancer-related fatigue on chemotherapy-induced nausea and vomiting in Asian cancer patients. Pharmacoepidemiol Drug Saf 2013;22(12):1345-51.
  45. Chan A, Chiang YY, Low XH, Yap K, Ng R. Affordability of Cancer Treatment For Aging Cancer Patients in Singapore: An Analysis of Health, Lifestyle, and Financial Burden. Support Care Cancer 2013;21(12):3509-17.
  46. Ng T, Cheung YT, Ng QS, Ho HK, Chan A. Vascular endothelial growth factor inhibitors and cognitive impairment: evidence and controversies. Expert Opin Drug Saf 2014; 13(1): 83-92.
  47. Cheung YT, Lim SR, Chui WK, Tan YP, Chan A. Psychometric properties and measurement equivalence of the English and Chinese versions of the functional assessment of cancer therapy-cognitive in Asian breast cancer patients. Value in Health 2013;16(6):1001-13.
  48. Wong RK, Bensadoun RJ, Boers-Doets CB, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Lacouture ME. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer 2013;21(10):2933-48.
  49. Lao CK, Ho SC, Chan KK, Tou CF, Tong HHY, Chan A. Potentially inappropriate prescribing and drug-drug interactions among elderly Chinese nursing home residents in Macao. Int J Clin Pharm 2013; 35(5):805-12
  50. Yap KY, Low XH, Koh KS, Un M, Shih V, Chan A. Feasibility and Acceptance of a Pharmacist-Run Tele-oncology Service for Chemotherapy-Induced Nausea and Vomiting in Ambulatory Cancer Patients. Telemed J E Health 2013;19(5):387-95.
  51. Chan A, Lee CP, Chiang J, Ng R. Breakthrough Febrile Neutropenia and Associated Complications Among Elderly Cancer Patients Receiving Myelosuppressive Chemotherapy for Solid Tumors and Lymphomas. Support Care Cancer 2013; 21(8): 2137-43.
  52. Cheung YT, Lee H, Chan A. Exploring clinical determinants and anxiety symptom domains among Asian breast cancer patients. Support Care Cancer 2013; 21(8):2185-94.
  53. Cheung YT, Shwe M, Tan E, Chui WK, Ng R, Chan A. Acknowledging the Relevance of Cognitive Changes in Cancer Patients: Perspectives of Oncology Practitioners in Asia. J Cancer Surviv. 2013;7(1):146-54.
  54. Chan A, Ho HK, Cheung YT, Teo YL. Supportive Care in Cancer Patients: Current Challenges and Opportunities. Adv Pharmacoepidem Drug Safety 2012; vol 1:e111. doi:10.4172/2167-1052.1000e111.
  55. Koomanan N, Ko Y, Yong WP, Ng R, Wong YP, Lim SW, Salim A, Chan A. Clinical Impact of Drug-Drug Interaction Between Aspirin and Prednisolone at a Cancer Center. Clin Ther 2012;34: 2259–2267.
  56. Cheung YT, Shwe M, Chui WK, Chay WY, Ang SF, Dent RA, Yap YS, Lo SK, Ng R, Chan A. Effects of chemotherapy and psychosocial distress on perceived cognitive disturbances in Asian breast cancer patients. Ann Pharmacother 2012; 46(12):1645-55.
  57. Chan A, Tan SH, Low XH, Yap KY. Antiemetic Effectiveness and Nausea and Vomiting Incidence During Capecitabine and Oxaliplatin Chemotherapy. Nurs Res2012; 61(6):405-412.
  58. Yap KYL, Low XH, Chan A. Exploring Chemotherapy-Induced Toxicities through Multivariate Projection of Risk Factors: Prediction of Nausea and Vomiting. Toxicol Res 2012; 28(2): 81-91.
  59. Cheung YT, Chan A. Linguistic validation of Functional Assessment of Cancer Therapy–Cognitive Function (FACT-Cog): Methodological concerns. Support Care Cancer 2012; 21(3):655-6.
  60. Teo YL, Ho HK, Chan A. Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis. Cancer Treatment Review 2013; 39(2):199-206.
  61. Chen C, Chan A, Yap K. Visualizing clinical predictors of febrile neutropenia in Asian cancer patients receiving myelosuppressive chemotherapy. J Oncol Pharm Pract 2013; 19(2):111-20.
  62. Ko Y, Tan SL, Chan A, Wong YP, Yong WP, Ng RC, Lim SW, Salim A. Prevalence of the Coprescription of Clinically Important Interacting Drug Combinations Involving Oral Anticancer Agents in Singapore: A Retrospective Database Study. Clin Ther 2012; 34(8):1696-704.
  63. Seah J, Lin K, Tai D, Lim ST, Chan A. Conservative Management of L-asparaginase-induced Hypertriglyceridemia in an Adult Patient: A Case Report and Review of Literature. Onkologie 2012; 35(10):596-8.
  64. Chan A, Shih V, Chiang J, Chew L, Tay K, Quek R, Tao M, Lim ST. Clinical pharmacy services and research for lymphoma patients at a cancer center. J Onc Pharm Pract 2013; 19(1): 24-30.
  65. Shih V, Chan A, Xie F, Yu K. Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore. Value in Health Regional Issue 2012; 1: 46-53.
  66. Shih V, Chan A, Xie F, Yu K. Health State Utility Assessment for Breast cancer. Value in Health Regional Issue 2012; 1: 93-97.
  67. Lopes G, Burke T, Pellissier J, Zhang XH, Dedhiya S, Chan A. Aprepitant for Patients Receiving Highly Emetogenic Chemotherapy: An Economic Analysis for Singapore. Value in Health Regional Issue 2012; 1: 66-74.
  68. Cheung YT, Shwe M, Tan YP, Fan G, Ng R, Chan A. Cognitive changes in multiethnic Asian breast cancer patients: a focus group study. Ann Oncol 2012; 23(10):2547-52.
  69. Chan A, Low XH, Yap KYL. Assessment of the Relationship between Adherence with Antiemetic Drug Therapy and Control of Nausea and Vomiting in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy. J Manag Care Pharm 2012; 18(5):385-94.
  70. Cheung YT, Tan EH, Chan A. An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors. Support Care Cancer 2012;20(7):1361-75.
  71. Chan A, Chen C, Chiang J, Tan SH, Ng R. Incidence of Febrile Neutropenia among Early Stage Breast Cancer Patients Receiving Anthracycline-based Chemotherapy. Support Care Cancer 2012; 20(7): 1525-32.
  72. Teo YL, Saetaew M, Chanthawong S, Yap YS, Chan EC, Ho HK, Chan A. Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. Breast Cancer Res Treat 2012; 133(2): 703-11.
  73. Yap K, Leong C, Chan A. Controlling Chemotherapy-Induced Nausea and Vomiting with Neurokinin-1 Receptor Antagonists in Patients on AC-Based Chemotherapy—Are We There Yet?Journal of Cancer Therapy 2012; 3(1): 90-102.
  74. Chan A, Tang T, Ng T, Shih V, Tay K, Quek R, Tao M, Lim ST. To SMILE or not: Supportive Care Matters. J Clin Oncol 2012; 30 (9): 1015-6.
  75. Chan A, Ng T, Yap KYL. Clinically-relevant anticancer-antidepressant drug interactions. Expert Opin Drug MetabToxicol 2011; 18(2): 165-74.
  76. Chiang J, Chan A, Lian T, Tay K, Quek R, Tao M, Lim ST. Management of Tumor Lysis Syndrome with a Single Fixed Dose of Rasburicase in Asian Lymphoma Patients: A Case Series and Review of Literature. Asia Pac J Clin Oncol 2011; 7: 351–356.
  77. Yap YK, Low XH, Chui WK, Chan A. Computational prediction of state anxiety in Asian patients with cancer susceptible to chemotherapy-induced nausea and vomiting. J Clin Psychopharmacol 2012;32(2):207-217.
  78. Chan A, Lin TH, Shih V, Ching TH, Chiang J. Clinical Outcomes Among Singaporean Cancer Patients Receiving Chemotherapy With Complementary and Alternative Medicine: A Cohort Study.Altern Ther Health Med 2012;18(1):12-7.
  79. Yap KYL, See CS, Kuo EY, Chui WK, Chan A. Utilizing mobile networks for the detection of clinically-relevant interactions between chemotherapy regimens and complementary and alternative medicines. J Altern Complement Med 2011; 18(2):165-74.
  80. Cheung YT, Chui WK, Chan A. Neuro-cognitive impairment in breast cancer patients: Pharmacological considerations. Crit Rev Oncol Hematol 2012; 83(1):99-111
  81. Yap KY, Chui WK, Chan A. Development of a chemotherapy regimen interaction database for the mobile internet: detecting interactions with psychotropics through OncoRx-MI. Inform Health Soc Care 2011;36(3):132-46.
  82. Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011;19(8):1079-95.
  83. Chan A, Yap KYL, Koh D, Low XH, Cheung YT. Electronic Database to Predict Drug-Drug Interactions Between Antidepressants and Oral Anticancer Drugs from a Cancer Centre in Singapore: Implications to Clinicians. Pharmacoepidemiol Drug Saf 2011; 20(9):939-47
  84. Lee J, Chan A. Polypharmacy in the elderly cancer patient: clinical implications and management. Lancet Oncology 2011;12(13):1249-5
  85. Chan A, Chiang J, Lew KY, Chay WY. Preventing Oxaliplatin-Induced Sensory Neurotoxicity: A Methodology Perspective. J Clin Oncol 2011; 29(16):e48.
  86. Ng TRD, Chan A. Dosing recommendations of targeted cancer therapies in patients with special needs: Evidence and Controversies. Crit Rev Oncol Hematol 2012; 81: 58-74.
  87. Chan A, Leng XZ, Chiang JYL, Tao M, Quek R, Tay K, Lim ST. A comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients. Asia Pac J Clin Oncol 2011;7(1):75-81.
  88. Ng JH, Ang XY, Tan SH, Tao M, Lim ST, Chan A. Breakthrough febrile neutropenia and associated complications in Non-Hodgkin’s Lymphoma patients receiving pegfilgrastim. Acta Haem 2011;125:107-114.
  89. Chan A, Tan EH. How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? Support Care Cancer 2011;19(10):1667-74.
  90. Chan QR, Chan A. Impact of Erythropoiesis-Simulating Agent prescribing at an Asian cancer centre, after release of safety advisories. J Onc Pharm Pract 2010; 17(4): 350-9.
  91. Cheung YT, Yap KYL, Chui WK, Chan A. Drug-Drug Interactions between Oral Antiepileptics and Oral Anticancer Drugs: Implications to Clinicians. European Neurology 2010; 64:88-94.
  92. Yap KYL, Yak XR, Shih V, Chui WK, Chan A. Application of unsupervised learning in clinical oncology practice – exploring anxiety characteristics in chemotherapy-induced nausea and vomiting through principal variables. Journal of Computing 2010; 2(7): 163-171.
  93. Yap KY, Ho YX, Chui WK, Chan A. Harnessing the internet cloud for managing drug interactions with chemotherapy regimens in patients with cancer suffering from depression. Acta Oncol 2010. DOI: 10.3109/02841861003801130.
  94. Chiang J, Chan A, Shih V, Hee SW, Tao M, Lim ST. A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center. Int J Hematol 2010; 91(5):826-30
  95. Chan A, Fu WH, Shih V, Chua JC, Tan SH, Ng R. Impact of colony stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. Support Care Cancer 2011; 19:497–504.
  96. Yap KYL, Raaj S, Chan A. OncoRx-IQ: A tool for quality assessment of online anticancer drug interactions. Int J Qual Health Care 2010; 22:93-106.
  97. Yap KYL, See CS, Chan A. Clinically-relevant chemotherapy interactions with complementary and alternative medicines in patients with cancer. Recent Patents on Food, Nutrition and Agriculture 2010; 2(1):12-55.
  98. Yap KYL, Chan A, Chui WK. Opinions on drug interaction sources in anticancer treatments and parameters for an oncology specific database by pharmacy practitioners in Asia. Health Services Insights 2010;3: 1-12.
  99. Yap KYL, Chan A, Chui WK, Chen YZ. Cancer informatics for the clinician: An interaction database for chemotherapy regimens and antiepileptic drugs. Seizure 2010;19: 59-67.
  100. Chan A, Yap KYL. Detection and management of oncology drug interactions: Can we do better? Maturitas 2010; 65(3):181-2.
  101. Chan A, Tan SH, Wong CM, Yap KY, Yu K. Clinically significantly drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists. Clin Ther 2009; 31: 2979-86.
  102. Yap KYL, Kuo EY, Lee JJ, Chui WK, Chan A. An onco-informatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: an overview of the OncoRx project. Support Care Cancer 2010; 18(7):883-91.
  103. Lam CK, Chiang J, Shih V, Chan A. The prevalence of complementary and alternative medicine (CAM) usage in Singaporean Breast Cancer patients. Asia Pacific Journal of Oncology and Hematology 2009; 1(3): 1-6.
  104. Tan EH, Chan A. Evidence based treatment options for the management of skin toxicities associated with EGFR inhibitors. Ann Pharmacother2009; 43:1658-66.
  105. Yap KYL, Chan A, Chui WK. Improving pharmaceutical care in oncology through pharmacoinformatics: the evolving role of informatics and the internet for drug therapy. Lancet Oncology 2009; 10:1011-19.
  106. Yap KYL, Chui WK, Tan WL, Chan A. Clinically relevant drug interactions between anticancer drugs and psychotropic agents. Eur J Cancer Care.2011;20(1):6-32
  107. Lai GG, Lim ST, Tao M, Chan A, Li H, Quek R. Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. Am J Hematol 2009; 84(7):414-7.
  108. Yap KYL, Chen YZ, Chui WK, Chan A. Oncoinformatics for the healthcare professional: oncology databases and blogs. Internet Journal of Oncology 2009;6(1):1-22. Available at:
  109. Chan A, Lim LL, Tao M. Utilisation Review of epoetin alfa in cancer patients at a cancer centre in Singapore. Singapore Med J 2009; 50(4): 365-70.
  110. Lee JYC, Tan F, Chan A. Evaluation of thiazolidinediones on cardiovascular outcomes in patients with type 2 diabetes mellitus: A systematic review. The Journal of Nursing Practitioner 2009; 5(3): 176-184.
  111. Shih V, Hee SW, Chan A. Clinical Predictors of Chemotherapy Induced Nausea and Vomiting (CINV) in Breast Cancer Patients Receiving Adjuvant Doxorubicin and Cyclophosphamide (AC) Chemotherapy. Ann Pharmacother 2009; 43:444-452.
  112. Chan A, Leow YC, Sim MH. Patients’ Perspectives and Safe Handling of Oral Anti-Cancer Drugs at an Asian Cancer Centre. J Oncol Pharm Pract 2009; 15:161–165.
  113. Shih V, Chiang JYL, Chan A. Complementary and alternative medicine (CAM) usage in Singaporean adult cancer patients. Ann Oncol 2009; 20: 752-757.
  114. Wong CM, Ko Y, Chan A. Clinically Significant Drug-Drug Interactions between Oral Anticancer Agents and Non-Anticancer Agents: Drug-Drug Interaction Profiling and Comparison of Two Drug Compendia. Ann Pharmacother 2008; 42:1737-1748.
  115. Yap KYL, Chui WK, Chan A. Drug interactions between chemotherapy regimens and antiepileptics. Clin Ther 2008; 8: 1387-407.
  116. Chan A, Shih V, Chew L. Evolving roles of oncology pharmacists in Singapore: A survey on prescribing patterns of antiemetics for Chemotherapy Induced Nausea and Vomiting (CINV) at a Cancer Centre. J Oncol Pharm Pract 2008; 14: 23-29.
  117. Chan A, Shih V, Tham CK. Liposomal doxorubicin associated acute hypersensitivity despite appropriate preventive measures. J Oncol Pharm Pract 2007; 13(2):105-7.
  118. Chan A, Iannucci A., Dager WE. Systemic Anticoagulant Prophylaxis for Central Catheter-Associated Venous Thrombosis in Cancer Patients. Ann Pharmacother 2007;41: 635-41.
  119. Elg C, Chan A, Hernandez L. The war on cancer: Now in a convenient tablet form. California Journal of Health Systems Pharmacists 2007; 19(2): 5-13.
  120. Chan A, Ignoffo RJ. Survey of Topical Oral Solutions for the treatment of Chemo-Induced Oral Mucositis. J Oncol Pharm Pract. 2005;11(4):139-43.
  121. Olin J, Chan A. Experience with nesiritide at a community hospital. Am J Health-Syst Pharm 2004; 61: 1337-8.
  122. Olin J, Chan A, Lazarus E. Pulmonary Edema and Possible Pneumonitis Associated with Celecoxib. Ann Pharmacother 2004; 38: 1086.